Literature DB >> 10434299

Polyglutamine pathogenesis.

C A Ross1, J D Wood, G Schilling, M F Peters, F C Nucifora, J K Cooper, A H Sharp, R L Margolis, D R Borchelt.   

Abstract

An increasing number of neurodegenerative disorders have been found to be caused by expanding CAG triplet repeats that code for polyglutamine. Huntington's disease (HD) is the most common of these disorders and dentatorubral-pallidoluysian atrophy (DRPLA) is very similar to HD, but is caused by mutation in a different gene, making them good models to study. In this review, we will concentrate on the roles of protein aggregation, nuclear localization and proteolytic processing in disease pathogenesis. In cell model studies of HD, we have found that truncated N-terminal portions of huntingtin (the HD gene product) with expanded repeats form more aggregates than longer or full length huntingtin polypeptides. These shorter fragments are also more prone to aggregate in the nucleus and cause more cell toxicity. Further experiments with huntingtin constructs harbouring exogenous nuclear import and nuclear export signals have implicated the nucleus in direct cell toxicity. We have made mouse models of HD and DRPLA using an N-terminal truncation of huntingtin (N171) and full-length atrophin-1 (the DRPLA gene product), respectively. In both models, diffuse neuronal nuclear staining and nuclear inclusion bodies are observed in animals expressing the expanded glutamine repeat protein, further implicating the nucleus as a primary site of neuronal dysfunction. Neuritic pathology is also observed in the HD mice. In the DRPLA mouse model, we have found that truncated fragments of atrophin-1 containing the glutamine repeat accumulate in the nucleus, suggesting that proteolysis may be critical for disease progression. Taken together, these data lead towards a model whereby proteolytic processing, nuclear localization and protein aggregation all contribute to pathogenesis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10434299      PMCID: PMC1692617          DOI: 10.1098/rstb.1999.0452

Source DB:  PubMed          Journal:  Philos Trans R Soc Lond B Biol Sci        ISSN: 0962-8436            Impact factor:   6.237


  72 in total

1.  HIP-I: a huntingtin interacting protein isolated by the yeast two-hybrid system.

Authors:  E E Wanker; C Rovira; E Scherzinger; R Hasenbank; S Wälter; D Tait; J Colicelli; H Lehrach
Journal:  Hum Mol Genet       Date:  1997-03       Impact factor: 6.150

2.  SH3 domain-dependent association of huntingtin with epidermal growth factor receptor signaling complexes.

Authors:  Y F Liu; R C Deth; D Devys
Journal:  J Biol Chem       Date:  1997-03-28       Impact factor: 5.157

3.  Intracellular aggregate formation of dentatorubral-pallidoluysian atrophy (DRPLA) protein with the extended polyglutamine.

Authors:  T Miyashita; K Nagao; K Ohmi; H Yanagisawa; Y Okamura-Oho; M Yamada
Journal:  Biochem Biophys Res Commun       Date:  1998-08-10       Impact factor: 3.575

4.  Nuclear inclusions of the androgen receptor protein in spinal and bulbar muscular atrophy.

Authors:  M Li; S Miwa; Y Kobayashi; D E Merry; M Yamamoto; F Tanaka; M Doyu; Y Hashizume; K H Fischbeck; G Sobue
Journal:  Ann Neurol       Date:  1998-08       Impact factor: 10.422

5.  A cellular model that recapitulates major pathogenic steps of Huntington's disease.

Authors:  A Lunkes; J L Mandel
Journal:  Hum Mol Genet       Date:  1998-09       Impact factor: 6.150

6.  Huntingtin interacts with a family of WW domain proteins.

Authors:  P W Faber; G T Barnes; J Srinidhi; J Chen; J F Gusella; M E MacDonald
Journal:  Hum Mol Genet       Date:  1998-09       Impact factor: 6.150

7.  Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice.

Authors:  I A Klement; P J Skinner; M D Kaytor; H Yi; S M Hersch; H B Clark; H Y Zoghbi; H T Orr
Journal:  Cell       Date:  1998-10-02       Impact factor: 41.582

8.  Behavioural abnormalities and selective neuronal loss in HD transgenic mice expressing mutated full-length HD cDNA.

Authors:  P H Reddy; M Williams; V Charles; L Garrett; L Pike-Buchanan; W O Whetsell; G Miller; D A Tagle
Journal:  Nat Genet       Date:  1998-10       Impact factor: 38.330

9.  Polyglutamine-expanded human huntingtin transgenes induce degeneration of Drosophila photoreceptor neurons.

Authors:  G R Jackson; I Salecker; X Dong; X Yao; N Arnheim; P W Faber; M E MacDonald; S L Zipursky
Journal:  Neuron       Date:  1998-09       Impact factor: 17.173

10.  Intranuclear neuronal inclusions in Huntington's disease and dentatorubral and pallidoluysian atrophy: correlation between the density of inclusions and IT15 CAG triplet repeat length.

Authors:  M W Becher; J A Kotzuk; A H Sharp; S W Davies; G P Bates; D L Price; C A Ross
Journal:  Neurobiol Dis       Date:  1998-04       Impact factor: 5.996

View more
  23 in total

1.  Human cytomegalovirus UL97 kinase prevents the deposition of mutant protein aggregates in cellular models of Huntington's disease and ataxia.

Authors:  Cristy Tower; Lianwu Fu; Rachel Gill; Mark Prichard; Mathieu Lesort; Elizabeth Sztul
Journal:  Neurobiol Dis       Date:  2010-08-20       Impact factor: 5.996

2.  Increased susceptibility of cytoplasmic over nuclear polyglutamine aggregates to autophagic degradation.

Authors:  Atsushi Iwata; John C Christianson; Mirella Bucci; Lisa M Ellerby; Nobuyuki Nukina; Lysia S Forno; Ron R Kopito
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-02       Impact factor: 11.205

Review 3.  Amyloidogenesis of natively unfolded proteins.

Authors:  Vladimir N Uversky
Journal:  Curr Alzheimer Res       Date:  2008-06       Impact factor: 3.498

Review 4.  The paradigm of Huntington's disease: therapeutic opportunities in neurodegeneration.

Authors:  Julie Leegwater-Kim; Jang-Ho J Cha
Journal:  NeuroRx       Date:  2004-01

5.  Altered transcription in yeast expressing expanded polyglutamine.

Authors:  R E Hughes; R S Lo; C Davis; A D Strand; C L Neal; J M Olson; S Fields
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-30       Impact factor: 11.205

6.  Transcriptional changes in Huntington disease identified using genome-wide expression profiling and cross-platform analysis.

Authors:  Kristina Becanovic; Mahmoud A Pouladi; Raymond S Lim; Alexandre Kuhn; Paul Pavlidis; Ruth Luthi-Carter; Michael R Hayden; Blair R Leavitt
Journal:  Hum Mol Genet       Date:  2010-01-20       Impact factor: 6.150

7.  Protein disorder in the human diseasome: unfoldomics of human genetic diseases.

Authors:  Uros Midic; Christopher J Oldfield; A Keith Dunker; Zoran Obradovic; Vladimir N Uversky
Journal:  BMC Genomics       Date:  2009-07-07       Impact factor: 3.969

Review 8.  Studying polyglutamine diseases in Drosophila.

Authors:  Zhen Xu; Antonio Joel Tito; Yan-Ning Rui; Sheng Zhang
Journal:  Exp Neurol       Date:  2015-08-06       Impact factor: 5.330

9.  RAN Translation in Huntington Disease.

Authors:  Monica Bañez-Coronel; Fatma Ayhan; Alex D Tarabochia; Tao Zu; Barbara A Perez; Solaleh Khoramian Tusi; Olga Pletnikova; David R Borchelt; Christopher A Ross; Russell L Margolis; Anthony T Yachnis; Juan C Troncoso; Laura P W Ranum
Journal:  Neuron       Date:  2015-11-18       Impact factor: 17.173

10.  Nucleocytoplasmic shuttling activity of ataxin-3.

Authors:  Sandra Macedo-Ribeiro; Luísa Cortes; Patrícia Maciel; Ana Luísa Carvalho
Journal:  PLoS One       Date:  2009-06-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.